Aryan Patel
Pronouns: He/Him
Research Mentor(s): Martin Myers Jr
Research Mentor School/College/Department: / Medicine
Program:
Authors:
Session: Session 6: 3:40 pm – 4:30 pm
Poster: 26
Abstract
While obesity and its associated complications, such as Type 2 diabetes, persist as major global health concerns, effective treatment options remain unavailable to many and have unpleasant side effects. Most of the current medications in use or in development, like calcitonin/amylin receptor (CALCR/AmyR) agonists and glucagon-like peptide-1 (GLP1R) agonists produce nausea or vomiting, that decrease patient compliance and thus overall effectiveness. Many neuronal populations in the dorsal vagal complex (DVC) of the hindbrain are involved in regulating energy expenditure and appetite suppression, making them ideal targets for weight loss medications (Ludwig, et al. 2020). This study focuses on comparing the DVC neuronal populations in diet-induced obese mice activated by treatment with a CALCR/AmyR agonist (compound -0833) alone and in combination with GLP1R agonist semaglutide. Specifically, this study aims to validate the appropriateness of the drug doses selected for our experiments by analyzing neuronal activation (using FOS immunohistochemistry) produced by each vehicle control, each drug alone, and the two drugs in combination.
